Search results for: 'Biological antibody reagents US'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) highlights recent advances in biological therapies such as RNA therapies, biosimilars, gene therapies and cell therapies for the management of diseases such as cancer, neurodegenerative disorders and rare diseases. The research also provides technological insigh...

Sepsis is a life-threatening condition caused by overactivation of host immune system upon infections which may lead to organ failure and potentially death. World Health Organization designates sepsis as a global public health priority. Several studies conducted to understand the molecular basis of sepsis, septic shock, and organ failure. Despite e...

Next-generation fermentation pathways for sustainable fuel production represent an evolving suite of biological and bio-electrochemical processes designed to convert diverse carbon sources, such as CO₂, biomass, waste gases, and organic residues, into liquid fuels. These approaches integrate advances in metabolic engineering, synthetic biology, and...

AI has moved from a standalone technology to a core building block that drives global business growth. AI adoption is increasingly critical for international businesses to stay competitive. Improved efficiency and productivity and the need to gain a competitive edge drive the rising adoption of AI among businesses. Understanding AI use cases and a...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights into recent technological developments for molecular marker detection, drug delivery, cancer immunotherapies and radiopharmaceuticals. The TOE also comprises analysis of innovations across cell and gene therapy, antibody and gene editing platfo...

The COVID-19 pandemic led to the rapid scaling up of production activities in the pharmaceutical industry. An increase in the number of FDA approvals in biologics has further accelerated biopharmaceutical production, particularly in North America and Asia. With a boom in biopharmaceuticals anticipated in the next 5 to 7 years, the demand for single...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) comprise innovation insights across antibody and cellular therapies. The study also encompasses recent innovations in liquid biopsy tests, drug delivery and drug discovery platforms.The Life Science, Health & Wellness TOE will feature disruptive technology advan...

Artificial intelligence (AI) is ushering in a new era of possibilities for intelligence gathering and analysis. While AI has been a part of the US Intelligence Community (IC) for some time, the rapid acceleration of AI capabilities is drastically transforming the landscape. The vast amount of information that the US IC collects from an array of se...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...